{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:52:12Z","timestamp":1770789132829,"version":"3.50.0"},"reference-count":150,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:p>\n                    <jats:bold>Context.\u2014<\/jats:bold>\n                    Precision medicine is the promise of individualized therapy and management of patients based on their personal biology. There are now multiple global initiatives to perform whole-genome sequencing on millions of individuals. In the United States, an early program was the Million Veteran Program, and a more recent proposal in 2015 by the president of the United States is the Precision Medicine Initiative. To implement precision medicine in routine oncology care, genetic variants present in tumors need to be matched with effective clinical therapeutics. When we focus on the current state of precision medicine for gastrointestinal malignancies, it becomes apparent that there is a mixed history of success and failure.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective.\u2014<\/jats:bold>\n                    To present the current state of precision medicine using gastrointestinal oncology as a model. We will present currently available targeted therapeutics, promising new findings in clinical genomic oncology, remaining quality issues in genomic testing, and emerging oncology clinical trial designs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Data Sources.\u2014<\/jats:bold>\n                    Review of the literature including clinical genomic studies on gastrointestinal malignancies, clinical oncology trials on therapeutics targeted to molecular alterations, and emerging clinical oncology study designs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.\u2014<\/jats:bold>\n                    Translating our ability to sequence thousands of genes into meaningful improvements in patient survival will be the challenge for the next decade.\n                  <\/jats:p>","DOI":"10.5858\/arpa.2015-0317-ra","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T16:37:50Z","timestamp":1461947870000},"page":"449-460","source":"Crossref","is-referenced-by-count":3,"title":["Precision Medicine in Gastrointestinal Pathology"],"prefix":"10.5858","volume":"140","author":[{"given":"David H.","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason Y.","family":"Park","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center and Dallas Veterans Affairs Medical Center, Dallas (Dr Wang);"},{"name":"and the Department of Pathology, Eugene McDermott Center for Human Growth and Development, Children's Medical Center, and University of Texas Southwestern Medical Center, Dallas (Dr Park)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","reference":[{"key":"i1543-2165-140-5-449-b01","series-title":"The adventure of the Abbey Grange. The Return of Sherlock Holmes","first-page":"319","author":"Doyle \n              AC.","year":"1905","unstructured":"Doyle \n              AC. \n            \n          \n          The adventure of the Abbey Grange. The Return of Sherlock Holmes. New York, NY: PF Collier & Son;1905:319\u2013348."},{"issue":"9","key":"i1543-2165-140-5-449-b02","series-title":"N Engl J Med","first-page":"793","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins \n              FS,","year":"2015","unstructured":"Collins \n              FS, \n            \n            \n              Varmus \n              H. \n            \n          \n          A new initiative on precision medicine. N Engl J Med. 2015;372(9):793\u2013795."},{"issue":"7549","key":"i1543-2165-140-5-449-b03","series-title":"Nature","first-page":"609","article-title":"Personalized medicine: time for one-person trials","volume":"520","author":"Schork \n              NJ.","year":"2015","unstructured":"Schork \n              NJ. \n            \n          \n          Personalized medicine: time for one-person trials. Nature. 2015;520(7549):609\u2013611."},{"key":"i1543-2165-140-5-449-b04","article-title":"US Department of Veterans Affairs Web site","year":"2015","unstructured":"Million Veteran Program (MVP). US Department of Veterans Affairs Web site. http:\/\/www.research.va.gov\/mvp\/. AccessedSeptember8,2015."},{"issue":"11","key":"i1543-2165-140-5-449-b05","series-title":"Blood","first-page":"4243","article-title":"Fifty years of studies of the biology and therapy of childhood leukemia","volume":"90","author":"Kersey \n              JH.","year":"1997","unstructured":"Kersey \n              JH. \n            \n          \n          Fifty years of studies of the biology and therapy of childhood leukemia. Blood. 1997;90(11):4243\u20134251."},{"issue":"14","key":"i1543-2165-140-5-449-b06","series-title":"Cancer","first-page":"2620","article-title":"Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis","volume":"119","author":"Brunner \n              AM,","year":"2013","unstructured":"Brunner \n              AM, \n            \n            \n              Campigotto \n              F, \n            \n            \n              Sadrzadeh \n              H, \n            \n            et al. \n          Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013;119(14):2620\u20132629."},{"issue":"23","key":"i1543-2165-140-5-449-b07","series-title":"N Engl J Med","first-page":"2408","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker \n              BJ,","year":"2006","unstructured":"Druker \n              BJ, \n            \n            \n              Guilhot \n              F, \n            \n            \n              O'Brien \n              SG, \n            \n            et al. \n          Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u20132417."},{"issue":"14","key":"i1543-2165-140-5-449-b08","series-title":"JAMA","first-page":"1430","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non\u2013small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis","volume":"311","author":"Lee \n              JK,","year":"2014","unstructured":"Lee \n              JK, \n            \n            \n              Hahn \n              S, \n            \n            \n              Kim \n              DW, \n            \n            et al. \n          Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non\u2013small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA. 2014;311(14):1430\u20131437."},{"issue":"6","key":"i1543-2165-140-5-449-b09","series-title":"N Engl J Med","first-page":"567","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner \n              JA,","year":"2006","unstructured":"Bonner \n              JA, \n            \n            \n              Harari \n              PM, \n            \n            \n              Giralt \n              J, \n            \n            et al. \n          Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567\u2013578."},{"issue":"1","key":"i1543-2165-140-5-449-b10","series-title":"Oncologist","first-page":"9","article-title":"Management of gastrointestinal stromal tumors in the imatinib era: selected case studies","volume":"11","author":"Benjamin \n              RS,","year":"2006","unstructured":"Benjamin \n              RS, \n            \n            \n              Blanke \n              CD, \n            \n            \n              Blay \n              JY, \n            \n            \n              Bonvalot \n              S, \n            \n            \n              Eisenberg \n              B. \n            \n          \n          Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. Oncologist. 2006;11(1):9\u201320."},{"issue":"14","key":"i1543-2165-140-5-449-b11","series-title":"N Engl J Med","first-page":"1052","article-title":"Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor","volume":"344","author":"Joensuu \n              H,","year":"2001","unstructured":"Joensuu \n              H, \n            \n            \n              Roberts \n              PJ, \n            \n            \n              Sarlomo-Rikala \n              M, \n            \n            et al. \n          Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344(14):1052\u20131056."},{"issue":"7","key":"i1543-2165-140-5-449-b12","series-title":"N Engl J Med","first-page":"472","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri \n              GD,","year":"2002","unstructured":"Demetri \n              GD, \n            \n            \n              von Mehren \n              M, \n            \n            \n              Blanke \n              CD, \n            \n            et al. \n          Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472\u2013480."},{"issue":"12","key":"i1543-2165-140-5-449-b13","series-title":"JAMA","first-page":"1265","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial","volume":"307","author":"Joensuu \n              H,","year":"2012","unstructured":"Joensuu \n              H, \n            \n            \n              Eriksson \n              M, \n            \n            \n              SundbyHall \n              K, \n            \n            et al. \n          One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265\u20131272."},{"key":"i1543-2165-140-5-449-b14","series-title":"NCCN clinical practice guidelines in oncology: soft tissue sarcoma","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: soft tissue sarcoma(version 1.2015). http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/sarcoma.pdf. Accessed October 14, 2015."},{"issue":"9863","key":"i1543-2165-140-5-449-b15","series-title":"Lancet","first-page":"295","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri \n              GD,","year":"2013","unstructured":"Demetri \n              GD, \n            \n            \n              Reichardt \n              P, \n            \n            \n              Kang \n              YK, \n            \n            et al. \n          Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295\u2013302."},{"issue":"1","key":"i1543-2165-140-5-449-b16","series-title":"BMC Cancer","first-page":"557","article-title":"Population-based SEER trend analysis of overall and cancer-specific survival in 5138 patients with gastrointestinal stromal tumor","volume":"15","author":"Guller \n              U,","year":"2015","unstructured":"Guller \n              U, \n            \n            \n              Tarantino \n              I, \n            \n            \n              Cerny \n              T, \n            \n            \n              Schmied \n              BM, \n            \n            \n              Warschkow \n              R. \n            \n          \n          Population-based SEER trend analysis of overall and cancer-specific survival in 5138 patients with gastrointestinal stromal tumor. BMC Cancer. 2015;15(1):557."},{"issue":"4","key":"i1543-2165-140-5-449-b17","series-title":"Gastrointest Endosc","first-page":"977","article-title":"Human epidermal growth factor receptor 2 testing in gastric and gastroesophageal junction adenocarcinomas: role of the gastroenterologist","volume":"81","author":"Park \n              JY,","year":"2015","unstructured":"Park \n              JY, \n            \n            \n              Dunbar \n              KB, \n            \n            \n              Vemulapalli \n              R, \n            \n            \n              Wang \n              DH, \n            \n            \n              Zhang \n              PJ. \n            \n          \n          Human epidermal growth factor receptor 2 testing in gastric and gastroesophageal junction adenocarcinomas: role of the gastroenterologist. Gastrointest Endosc. 2015;81(4):977\u2013982."},{"issue":"9911","key":"i1543-2165-140-5-449-b18","series-title":"Lancet","first-page":"31","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs \n              CS,","year":"2014","unstructured":"Fuchs \n              CS, \n            \n            \n              Tomasek \n              J, \n            \n            \n              Yong \n              CJ, \n            \n            et al. \n          Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31\u201339."},{"issue":"11","key":"i1543-2165-140-5-449-b19","series-title":"Lancet Oncol","first-page":"1224","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke \n              H,","year":"2014","unstructured":"Wilke \n              H, \n            \n            \n              Muro \n              K, \n            \n            \n              Van Cutsem \n              E, \n            \n            et al. \n          Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224\u20131235."},{"issue":"15","key":"i1543-2165-140-5-449-b20","series-title":"J Clin Oncol","first-page":"1960","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore \n              MJ,","year":"2007","unstructured":"Moore \n              MJ, \n            \n            \n              Goldstein \n              D, \n            \n            \n              Hamm \n              J, \n            \n            et al. \n          Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960\u20131966."},{"issue":"4","key":"i1543-2165-140-5-449-b21","series-title":"N Engl J Med","first-page":"378","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet \n              JM,","year":"2008","unstructured":"Llovet \n              JM, \n            \n            \n              Ricci \n              S, \n            \n            \n              Mazzaferro \n              V, \n            \n            et al. \n          Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u2013390."},{"issue":"5","key":"i1543-2165-140-5-449-b22","series-title":"Dig Dis Sci","first-page":"1122","article-title":"Sorafenib for treatment of hepatocellular carcinoma: a systematic review","volume":"57","author":"Xie \n              B,","year":"2012","unstructured":"Xie \n              B, \n            \n            \n              Wang \n              DH, \n            \n            \n              Spechler \n              SJ. \n            \n          \n          Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci. 2012;57(5):1122\u20131129."},{"issue":"7","key":"i1543-2165-140-5-449-b23","series-title":"Lancet Oncol","first-page":"627","article-title":"Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2\/3 randomised trial","volume":"14","author":"Crosby \n              T,","year":"2013","unstructured":"Crosby \n              T, \n            \n            \n              Hurt \n              CN, \n            \n            \n              Falk \n              S, \n            \n            et al. \n          Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2\/3 randomised trial. Lancet Oncol. 2013;14(7):627\u2013637."},{"issue":"3 suppl","key":"i1543-2165-140-5-449-b24","series-title":"J Clin Oncol","article-title":"The initial report of RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery","volume":"32","author":"Suntharalingam \n              M,","year":"2014","unstructured":"Suntharalingam \n              M, \n            \n            \n              Winter \n              K, \n            \n            \n              Ilson \n              DH, \n            \n            et al. \n          The initial report of RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery. J Clin Oncol. 2014;32(3 suppl):LBA6."},{"issue":"6","key":"i1543-2165-140-5-449-b25","series-title":"Lancet Oncol","first-page":"481","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial","volume":"14","author":"Waddell \n              T,","year":"2013","unstructured":"Waddell \n              T, \n            \n            \n              Chau \n              I, \n            \n            \n              Cunningham \n              D, \n            \n            et al. \n          Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):481\u2013489."},{"issue":"6","key":"i1543-2165-140-5-449-b26","series-title":"Am Fam Physician","first-page":"1759","article-title":"Update on colorectal cancer","volume":"61","author":"Rudy \n              DR,","year":"2000","unstructured":"Rudy \n              DR, \n            \n            \n              Zdon \n              MJ. \n            \n          \n          Update on colorectal cancer. Am Fam Physician. 2000;61(6):1759\u20131770, 1773\u20131774."},{"issue":"13","key":"i1543-2165-140-5-449-b27","series-title":"N Engl J Med","first-page":"905","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: irinotecan study group","volume":"343","author":"Saltz \n              LB,","year":"2000","unstructured":"Saltz \n              LB, \n            \n            \n              Cox \n              JV, \n            \n            \n              Blanke \n              C, \n            \n            et al. \n          Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: irinotecan study group. N Engl J Med. 2000;343(13):905\u2013914."},{"issue":"9209","key":"i1543-2165-140-5-449-b28","series-title":"Lancet","first-page":"1041","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard \n              JY,","year":"2000","unstructured":"Douillard \n              JY, \n            \n            \n              Cunningham \n              D, \n            \n            \n              Roth \n              AD, \n            \n            et al. \n          Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041\u20131047."},{"issue":"14S","key":"i1543-2165-140-5-449-b29","series-title":"J Clin Oncol","first-page":"3621","article-title":"N9741: FOLFOX (oxaliplatin (Oxal)\/5-fluorouracil (5-FU)\/leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU\/LV) in advanced colorectal cancer (CRC): final efficacy data from an intergroup study","volume":"22","author":"Goldberg \n              RM,","year":"2004","unstructured":"Goldberg \n              RM, \n            \n            \n              Sargent \n              DJ, \n            \n            \n              Morton \n              RF, \n            \n            et al. \n          N9741: FOLFOX (oxaliplatin (Oxal)\/5-fluorouracil (5-FU)\/leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU\/LV) in advanced colorectal cancer (CRC): final efficacy data from an intergroup study. J Clin Oncol. 2004;22(14S):3621."},{"issue":"16","key":"i1543-2165-140-5-449-b30","series-title":"J Clin Oncol","first-page":"2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont \n              A,","year":"2000","unstructured":"de Gramont \n              A, \n            \n            \n              Figer \n              A, \n            \n            \n              Seymour \n              M, \n            \n            et al. \n          Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938\u20132947."},{"issue":"1","key":"i1543-2165-140-5-449-b31","series-title":"J Clin Oncol","first-page":"136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti \n              S,","year":"2000","unstructured":"Giacchetti \n              S, \n            \n            \n              Perpoint \n              B, \n            \n            \n              Zidani \n              R, \n            \n            et al. \n          Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18(1):136\u2013147."},{"issue":"23","key":"i1543-2165-140-5-449-b32","series-title":"N Engl J Med","first-page":"2343","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andre \n              T,","year":"2004","unstructured":"Andre \n              T, \n            \n            \n              Boni \n              C, \n            \n            \n              Mounedji-Boudiaf \n              L, \n            \n            et al. \n          Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343\u20132351."},{"issue":"2","key":"i1543-2165-140-5-449-b33","series-title":"J Clin Oncol","first-page":"229","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand \n              C,","year":"2004","unstructured":"Tournigand \n              C, \n            \n            \n              Andre \n              T, \n            \n            \n              Achille \n              E, \n            \n            et al. \n          FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229\u2013237."},{"issue":"12","key":"i1543-2165-140-5-449-b34","series-title":"J Clin Oncol","first-page":"2006","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy \n              J,","year":"2008","unstructured":"Cassidy \n              J, \n            \n            \n              Clarke \n              S, \n            \n            \n              Diaz-Rubio \n              E, \n            \n            et al. \n          Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26(12):2006\u20132012."},{"issue":"4","key":"i1543-2165-140-5-449-b35","series-title":"Am J Clin Oncol","first-page":"350","article-title":"Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results","volume":"30","author":"Patt \n              YZ,","year":"2007","unstructured":"Patt \n              YZ, \n            \n            \n              Lee \n              FC, \n            \n            \n              Liebmann \n              JE, \n            \n            et al. \n          Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol. 2007;30(4):350\u2013357."},{"issue":"23","key":"i1543-2165-140-5-449-b36","series-title":"N Engl J Med","first-page":"2335","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz \n              H,","year":"2004","unstructured":"Hurwitz \n              H, \n            \n            \n              Fehrenbacher \n              L, \n            \n            \n              Novotny \n              W, \n            \n            et al. \n          Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335\u20132342."},{"issue":"12","key":"i1543-2165-140-5-449-b37","series-title":"J Clin Oncol","first-page":"2013","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz \n              LB,","year":"2008","unstructured":"Saltz \n              LB, \n            \n            \n              Clarke \n              S, \n            \n            \n              Diaz-Rubio \n              E, \n            \n            et al. \n          Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013\u20132019."},{"issue":"suppl 3","key":"i1543-2165-140-5-449-b38","series-title":"J Clin Oncol","first-page":"512","article-title":"RAISE: a randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp) [abstract]","volume":"33","author":"Tabernero \n              J,","year":"2015","unstructured":"Tabernero \n              J, \n            \n            \n              Cohn \n              A, \n            \n            \n              Obermannova \n              R, \n            \n            \n              Bodoky \n              G, \n            \n            \n              Garcia-Carbonero \n              R, \n            \n            \n              Ciuleanu \n              T. \n            \n          \n          RAISE: a randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp) [abstract]. J Clin Oncol. 2015;33(suppl 3):512."},{"issue":"15","key":"i1543-2165-140-5-449-b39","series-title":"J Clin Oncol","first-page":"2011","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem \n              E,","year":"2011","unstructured":"Van Cutsem \n              E, \n            \n            \n              Kohne \n              CH, \n            \n            \n              Lang \n              I, \n            \n            et al. \n          Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011\u20132019."},{"issue":"31","key":"i1543-2165-140-5-449-b40","series-title":"J Clin Oncol","first-page":"4706","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters \n              M,","year":"2010","unstructured":"Peeters \n              M, \n            \n            \n              Price \n              TJ, \n            \n            \n              Cervantes \n              A, \n            \n            et al. \n          Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4706\u20134713."},{"issue":"13","key":"i1543-2165-140-5-449-b41","series-title":"J Clin Oncol","first-page":"1658","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem \n              E,","year":"2007","unstructured":"Van Cutsem \n              E, \n            \n            \n              Peeters \n              M, \n            \n            \n              Siena \n              S, \n            \n            et al. \n          Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658\u20131664."},{"issue":"5","key":"i1543-2165-140-5-449-b42","series-title":"J Clin Oncol","first-page":"672","article-title":"A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer","volume":"27","author":"Hecht \n              JR,","year":"2009","unstructured":"Hecht \n              JR, \n            \n            \n              Mitchell \n              E, \n            \n            \n              Chidiac \n              T, \n            \n            et al. \n          A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27(5):672\u2013680."},{"issue":"6","key":"i1543-2165-140-5-449-b43","series-title":"N Engl J Med","first-page":"563","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol \n              J,","year":"2009","unstructured":"Tol \n              J, \n            \n            \n              Koopman \n              M, \n            \n            \n              Cats \n              A, \n            \n            et al. \n          Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360(6):563\u2013572."},{"issue":"9863","key":"i1543-2165-140-5-449-b44","series-title":"Lancet","first-page":"303","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey \n              A,","year":"2013","unstructured":"Grothey \n              A, \n            \n            \n              Van Cutsem \n              E, \n            \n            \n              Sobrero \n              A, \n            \n            et al. \n          Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303\u2013312."},{"issue":"13","key":"i1543-2165-140-5-449-b45","series-title":"JAMA","first-page":"1383","article-title":"Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial","volume":"307","author":"Alberts \n              SR,","year":"2012","unstructured":"Alberts \n              SR, \n            \n            \n              Sargent \n              DJ, \n            \n            \n              Nair \n              S, \n            \n            et al. \n          Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307(13):1383\u20131393."},{"issue":"13","key":"i1543-2165-140-5-449-b46","series-title":"JAMA","first-page":"1431","article-title":"Antitumor activity in metastatic disease does not predict efficacy in the adjuvant setting","volume":"307","author":"Segal \n              NH,","year":"2012","unstructured":"Segal \n              NH, \n            \n            \n              Saltz \n              LB. \n            \n          \n          Antitumor activity in metastatic disease does not predict efficacy in the adjuvant setting. JAMA. 2012;307(13):1431\u20131432."},{"issue":"23","key":"i1543-2165-140-5-449-b47","series-title":"J Clin Oncol","first-page":"3456","article-title":"Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803","volume":"25","author":"Saltz \n              LB,","year":"2007","unstructured":"Saltz \n              LB, \n            \n            \n              Niedzwiecki \n              D, \n            \n            \n              Hollis \n              D, \n            \n            et al. \n          Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25(23):3456\u20133461."},{"issue":"1","key":"i1543-2165-140-5-449-b48","series-title":"J Clin Oncol","first-page":"11","article-title":"Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08","volume":"29","author":"Allegra \n              CJ,","year":"2011","unstructured":"Allegra \n              CJ, \n            \n            \n              Yothers \n              G, \n            \n            \n              O'Connell \n              MJ, \n            \n            et al. \n          Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29(1):11\u201316."},{"issue":"15s","key":"i1543-2165-140-5-449-b49","series-title":"J Clin Oncol","first-page":"3534","article-title":"PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors [abstract]","volume":"28","author":"Kopetz \n              S,","year":"2010","unstructured":"Kopetz \n              S, \n            \n            \n              Desai \n              J, \n            \n            \n              Chan \n              E, \n            \n            et al. \n          PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors [abstract]. J Clin Oncol. 2010;28(15s):3534."},{"issue":"2","key":"i1543-2165-140-5-449-b50","series-title":"J Natl Cancer Inst","first-page":"84","article-title":"Ready or not: personal tumor profiling tests take off","volume":"103","author":"Garber \n              K.","year":"2011","unstructured":"Garber \n              K. \n            \n          \n          Ready or not: personal tumor profiling tests take off. J Natl Cancer Inst. 2011;103(2):84\u201386."},{"issue":"3","key":"i1543-2165-140-5-449-b51","series-title":"Crit Rev Oncol Hematol","first-page":"243","article-title":"Cancer of unknown primary (CUP)","volume":"54","author":"Pavlidis \n              N,","year":"2005","unstructured":"Pavlidis \n              N, \n            \n            \n              Fizazi \n              K. \n            \n          \n          Cancer of unknown primary (CUP). Crit Rev Oncol Hematol. 2005;54(3):243\u2013250."},{"issue":"1","key":"i1543-2165-140-5-449-b52","series-title":"JAMA Oncol","first-page":"40","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies","volume":"1","author":"Ross \n              JS,","year":"2015","unstructured":"Ross \n              JS, \n            \n            \n              Wang \n              K, \n            \n            \n              Gay \n              L, \n            \n            et al. \n          Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol. 2015;1(1):40\u201349."},{"issue":"4","key":"i1543-2165-140-5-449-b53","series-title":"JAMA Oncol","first-page":"466","article-title":"Whole-exome sequencing of metastatic cancer and biomarkers of treatment response","volume":"1","author":"Beltran \n              H,","year":"2015","unstructured":"Beltran \n              H, \n            \n            \n              Eng \n              K, \n            \n            \n              Mosquera \n              JM, \n            \n            et al. \n          Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol. 2015;1(4):466\u2013474."},{"issue":"12","key":"i1543-2165-140-5-449-b54","series-title":"Drug Discov Today","first-page":"1433","volume":"20","author":"Johnson \n              A,","unstructured":"Johnson \n              A, \n            \n            \n              Zeng \n              J, \n            \n            \n              Bailey \n              AM, \n            \n            et al. \n          The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discov Today. 20(12):1433\u20131438."},{"issue":"suppl 2","key":"i1543-2165-140-5-449-b55","series-title":"Cancer Inform","first-page":"45","article-title":"GeneMed: an informatics hub for the coordination of next-generation sequencing studies that support precision oncology clinical trials","volume":"14","author":"Zhao \n              Y,","year":"2015","unstructured":"Zhao \n              Y, \n            \n            \n              Polley \n              EC, \n            \n            \n              Li \n              MC, \n            \n            et al. \n          GeneMed: an informatics hub for the coordination of next-generation sequencing studies that support precision oncology clinical trials. Cancer Inform. 2015;14(suppl 2):45\u201355."},{"issue":"10","key":"i1543-2165-140-5-449-b56","series-title":"Nat Biotechnol","first-page":"908","article-title":"Performance comparison of exome DNA sequencing technologies","volume":"29","author":"Clark \n              MJ,","year":"2011","unstructured":"Clark \n              MJ, \n            \n            \n              Chen \n              R, \n            \n            \n              Lam \n              HY, \n            \n            et al. \n          Performance comparison of exome DNA sequencing technologies. Nat Biotechnol. 2011;29(10):908\u2013914."},{"issue":"1","key":"i1543-2165-140-5-449-b57","series-title":"Clin Chem","first-page":"213","article-title":"Clinical exome performance for reporting secondary genetic findings","volume":"61","author":"Park \n              JY,","year":"2015","unstructured":"Park \n              JY, \n            \n            \n              Clark \n              P, \n            \n            \n              Londin \n              E, \n            \n            \n              Sponziello \n              M, \n            \n            \n              Kricka \n              LJ, \n            \n            \n              Fortina \n              P. \n            \n          \n          Clinical exome performance for reporting secondary genetic findings. Clin Chem. 2015;61(1):213\u2013220."},{"issue":"1","key":"i1543-2165-140-5-449-b58","series-title":"Genome Med","first-page":"71","article-title":"Achieving high-sensitivity for clinical applications using augmented exome sequencing","volume":"7","author":"Patwardhan \n              A,","year":"2015","unstructured":"Patwardhan \n              A, \n            \n            \n              Harris \n              J, \n            \n            \n              Leng \n              N, \n            \n            et al. \n          Achieving high-sensitivity for clinical applications using augmented exome sequencing. Genome Med. 2015;7(1):71."},{"key":"i1543-2165-140-5-449-b59","series-title":"BMC Bioinformatics","first-page":"195","article-title":"Quantifying single nucleotide variant detection sensitivity in exome sequencing","volume":"14","author":"Meynert \n              AM,","year":"2013","unstructured":"Meynert \n              AM, \n            \n            \n              Bicknell \n              LS, \n            \n            \n              Hurles \n              ME, \n            \n            \n              Jackson \n              AP, \n            \n            \n              Taylor \n              MS. \n            \n          \n          Quantifying single nucleotide variant detection sensitivity in exome sequencing. BMC Bioinformatics. 2013;14:195."},{"issue":"1","key":"i1543-2165-140-5-449-b60","series-title":"Genome Med","first-page":"80","article-title":"Next-generation sequencing to guide cancer therapy","volume":"7","author":"Gagan \n              J,","year":"2015","unstructured":"Gagan \n              J, \n            \n            \n              Van Allen \n              EM. \n            \n          \n          Next-generation sequencing to guide cancer therapy. Genome Med. 2015;7(1):80."},{"issue":"4","key":"i1543-2165-140-5-449-b61","series-title":"Arch Pathol Lab Med","first-page":"481","article-title":"College of American Pathologists' laboratory standards for next-generation sequencing clinical tests","volume":"139","author":"Aziz \n              N,","year":"2015","unstructured":"Aziz \n              N, \n            \n            \n              Zhao \n              Q, \n            \n            \n              Bry \n              L, \n            \n            et al. \n          College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med. 2015;139(4):481\u2013493."},{"issue":"4","key":"i1543-2165-140-5-449-b62","series-title":"Cancers (Basel)","first-page":"2296","article-title":"Next-generation sequencing in clinical oncology: next steps towards clinical validation","volume":"6","author":"Bennett \n              NC,","year":"2014","unstructured":"Bennett \n              NC, \n            \n            \n              Farah \n              CS. \n            \n          \n          Next-generation sequencing in clinical oncology: next steps towards clinical validation. Cancers (Basel). 2014;6(4):2296\u20132312."},{"issue":"5","key":"i1543-2165-140-5-449-b63","series-title":"Cancer Treat Rev","first-page":"385","article-title":"The landscape of precision cancer medicine clinical trials in the United States","volume":"41","author":"Roper \n              N,","year":"2015","unstructured":"Roper \n              N, \n            \n            \n              Stensland \n              KD, \n            \n            \n              Hendricks \n              R, \n            \n            \n              Galsky \n              MD. \n            \n          \n          The landscape of precision cancer medicine clinical trials in the United States. Cancer Treat Rev. 2015;41(5):385\u2013390."},{"key":"i1543-2165-140-5-449-b64","series-title":"Annu Rev Pharmacol Toxicol","first-page":"9","article-title":"The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication","volume":"54","author":"Rask-Andersen \n              M,","year":"2014","unstructured":"Rask-Andersen \n              M, \n            \n            \n              Masuram \n              S, \n            \n            \n              Schioth \n              HB. \n            \n          \n          The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu Rev Pharmacol Toxicol. 2014;54:9\u201326."},{"key":"i1543-2165-140-5-449-b65","series-title":"Clin Chim Acta","first-page":"284","article-title":"The future of laboratory medicine\u2014a 2014 perspective","volume":"438","author":"Kricka \n              LJ,","year":"2015","unstructured":"Kricka \n              LJ, \n            \n            \n              Polsky \n              TG, \n            \n            \n              Park \n              JY, \n            \n            \n              Fortina \n              P. \n            \n          \n          The future of laboratory medicine\u2014a 2014 perspective. Clin Chim Acta. 2015;438:284\u2013303."},{"issue":"5","key":"i1543-2165-140-5-449-b66","series-title":"Mol Oncol","first-page":"967","article-title":"Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity","volume":"9","author":"Catenacci \n              DV.","year":"2015","unstructured":"Catenacci \n              DV. \n            \n          \n          Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol. 2015;9(5):967\u2013996."},{"issue":"133","key":"i1543-2165-140-5-449-b67","series-title":"Eur Respir Rev","first-page":"367","article-title":"New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response","volume":"23","author":"Menis \n              J,","year":"2014","unstructured":"Menis \n              J, \n            \n            \n              Hasan \n              B, \n            \n            \n              Besse \n              B. \n            \n          \n          New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. Eur Respir Rev. 2014;23(133):367\u2013378."},{"key":"i1543-2165-140-5-449-b68","series-title":"Am Soc Clin Oncol Educ Book","first-page":"71","article-title":"National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network","author":"Abrams \n              J,","year":"2014","unstructured":"Abrams \n              J, \n            \n            \n              Conley \n              B, \n            \n            \n              Mooney \n              M, \n            \n            et al. \n          National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book. 2014:71\u201376."},{"issue":"7","key":"i1543-2165-140-5-449-b69","series-title":"Cancer Discov","first-page":"685","article-title":"NCI prepares to launch MATCH trial","volume":"5","year":"2015","unstructured":"NCI prepares to launch MATCH trial. Cancer Discov. 2015;5(7):685."},{"issue":"3","key":"i1543-2165-140-5-449-b70","series-title":"Semin Oncol","first-page":"297","article-title":"Molecular analysis for therapy choice: NCI MATCH","volume":"41","author":"Conley \n              BA,","year":"2014","unstructured":"Conley \n              BA, \n            \n            \n              Doroshow \n              JH. \n            \n          \n          Molecular analysis for therapy choice: NCI MATCH. Semin Oncol. 2014;41(3):297\u2013299."},{"issue":"7","key":"i1543-2165-140-5-449-b71","series-title":"J Natl Cancer Inst","article-title":"NCI-MATCH launch highlights new trial design in precision-medicine era","volume":"107","author":"McNeil \n              C.","year":"2015","unstructured":"McNeil \n              C. \n            \n          \n          NCI-MATCH launch highlights new trial design in precision-medicine era. J Natl Cancer Inst. 2015;107(7):djv193."},{"issue":"9","key":"i1543-2165-140-5-449-b72","series-title":"J Clin Oncol","first-page":"1000","article-title":"Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial","volume":"33","author":"Lopez-Chavez \n              A,","year":"2015","unstructured":"Lopez-Chavez \n              A, \n            \n            \n              Thomas \n              A, \n            \n            \n              Rajan \n              A, \n            \n            et al. \n          Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol. 2015;33(9):1000\u20131007."},{"issue":"9","key":"i1543-2165-140-5-449-b73","series-title":"J Clin Oncol","first-page":"975","article-title":"Basket trials and the evolution of clinical trial design in an era of genomic medicine","volume":"33","author":"Redig \n              AJ,","year":"2015","unstructured":"Redig \n              AJ, \n            \n            \n              Janne \n              PA. \n            \n          \n          Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol. 2015;33(9):975\u2013977."},{"issue":"9","key":"i1543-2165-140-5-449-b74","series-title":"Clin Cancer Res","first-page":"2029","article-title":"Precision medicine for advanced pancreas cancer: the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial","volume":"21","author":"Chantrill \n              LA,","year":"2015","unstructured":"Chantrill \n              LA, \n            \n            \n              Nagrial \n              AM, \n            \n            \n              Watson \n              C, \n            \n            et al. \n          Precision medicine for advanced pancreas cancer: the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial. Clin Cancer Res. 2015;21(9):2029\u20132037."},{"issue":"8","key":"i1543-2165-140-5-449-b75","series-title":"Nat Rev Cancer","first-page":"457","article-title":"Evolving synergistic combinations of targeted immunotherapies to combat cancer","volume":"15","author":"Melero \n              I,","year":"2015","unstructured":"Melero \n              I, \n            \n            \n              Berman \n              DM, \n            \n            \n              Aznar \n              MA, \n            \n            \n              Korman \n              AJ, \n            \n            \n              Gracia \n              JL, \n            \n            \n              Haanen \n              J. \n            \n          \n          Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457\u2013472."},{"key":"i1543-2165-140-5-449-b01","series-title":"The adventure of the Abbey Grange. The Return of Sherlock Holmes","first-page":"319","author":"Doyle \n              AC.","year":"1905","unstructured":"Doyle \n              AC. \n            \n          \n          The adventure of the Abbey Grange. The Return of Sherlock Holmes. New York, NY: PF Collier & Son;1905:319\u2013348."},{"issue":"9","key":"i1543-2165-140-5-449-b02","series-title":"N Engl J Med","first-page":"793","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins \n              FS,","year":"2015","unstructured":"Collins \n              FS, \n            \n            \n              Varmus \n              H. \n            \n          \n          A new initiative on precision medicine. N Engl J Med. 2015;372(9):793\u2013795."},{"issue":"7549","key":"i1543-2165-140-5-449-b03","series-title":"Nature","first-page":"609","article-title":"Personalized medicine: time for one-person trials","volume":"520","author":"Schork \n              NJ.","year":"2015","unstructured":"Schork \n              NJ. \n            \n          \n          Personalized medicine: time for one-person trials. Nature. 2015;520(7549):609\u2013611."},{"key":"i1543-2165-140-5-449-b04","article-title":"US Department of Veterans Affairs Web site","year":"2015","unstructured":"Million Veteran Program (MVP). US Department of Veterans Affairs Web site. http:\/\/www.research.va.gov\/mvp\/. AccessedSeptember8,2015."},{"issue":"11","key":"i1543-2165-140-5-449-b05","series-title":"Blood","first-page":"4243","article-title":"Fifty years of studies of the biology and therapy of childhood leukemia","volume":"90","author":"Kersey \n              JH.","year":"1997","unstructured":"Kersey \n              JH. \n            \n          \n          Fifty years of studies of the biology and therapy of childhood leukemia. Blood. 1997;90(11):4243\u20134251."},{"issue":"14","key":"i1543-2165-140-5-449-b06","series-title":"Cancer","first-page":"2620","article-title":"Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis","volume":"119","author":"Brunner \n              AM,","year":"2013","unstructured":"Brunner \n              AM, \n            \n            \n              Campigotto \n              F, \n            \n            \n              Sadrzadeh \n              H, \n            \n            et al. \n          Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013;119(14):2620\u20132629."},{"issue":"23","key":"i1543-2165-140-5-449-b07","series-title":"N Engl J Med","first-page":"2408","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker \n              BJ,","year":"2006","unstructured":"Druker \n              BJ, \n            \n            \n              Guilhot \n              F, \n            \n            \n              O'Brien \n              SG, \n            \n            et al. \n          Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u20132417."},{"issue":"14","key":"i1543-2165-140-5-449-b08","series-title":"JAMA","first-page":"1430","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non\u2013small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis","volume":"311","author":"Lee \n              JK,","year":"2014","unstructured":"Lee \n              JK, \n            \n            \n              Hahn \n              S, \n            \n            \n              Kim \n              DW, \n            \n            et al. \n          Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non\u2013small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA. 2014;311(14):1430\u20131437."},{"issue":"6","key":"i1543-2165-140-5-449-b09","series-title":"N Engl J Med","first-page":"567","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner \n              JA,","year":"2006","unstructured":"Bonner \n              JA, \n            \n            \n              Harari \n              PM, \n            \n            \n              Giralt \n              J, \n            \n            et al. \n          Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567\u2013578."},{"issue":"1","key":"i1543-2165-140-5-449-b10","series-title":"Oncologist","first-page":"9","article-title":"Management of gastrointestinal stromal tumors in the imatinib era: selected case studies","volume":"11","author":"Benjamin \n              RS,","year":"2006","unstructured":"Benjamin \n              RS, \n            \n            \n              Blanke \n              CD, \n            \n            \n              Blay \n              JY, \n            \n            \n              Bonvalot \n              S, \n            \n            \n              Eisenberg \n              B. \n            \n          \n          Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. Oncologist. 2006;11(1):9\u201320."},{"issue":"14","key":"i1543-2165-140-5-449-b11","series-title":"N Engl J Med","first-page":"1052","article-title":"Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor","volume":"344","author":"Joensuu \n              H,","year":"2001","unstructured":"Joensuu \n              H, \n            \n            \n              Roberts \n              PJ, \n            \n            \n              Sarlomo-Rikala \n              M, \n            \n            et al. \n          Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344(14):1052\u20131056."},{"issue":"7","key":"i1543-2165-140-5-449-b12","series-title":"N Engl J Med","first-page":"472","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri \n              GD,","year":"2002","unstructured":"Demetri \n              GD, \n            \n            \n              von Mehren \n              M, \n            \n            \n              Blanke \n              CD, \n            \n            et al. \n          Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472\u2013480."},{"issue":"12","key":"i1543-2165-140-5-449-b13","series-title":"JAMA","first-page":"1265","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial","volume":"307","author":"Joensuu \n              H,","year":"2012","unstructured":"Joensuu \n              H, \n            \n            \n              Eriksson \n              M, \n            \n            \n              SundbyHall \n              K, \n            \n            et al. \n          One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265\u20131272."},{"key":"i1543-2165-140-5-449-b14","series-title":"NCCN clinical practice guidelines in oncology: soft tissue sarcoma","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: soft tissue sarcoma(version 1.2015). http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/sarcoma.pdf. Accessed October 14, 2015."},{"issue":"9863","key":"i1543-2165-140-5-449-b15","series-title":"Lancet","first-page":"295","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri \n              GD,","year":"2013","unstructured":"Demetri \n              GD, \n            \n            \n              Reichardt \n              P, \n            \n            \n              Kang \n              YK, \n            \n            et al. \n          Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295\u2013302."},{"issue":"1","key":"i1543-2165-140-5-449-b16","series-title":"BMC Cancer","first-page":"557","article-title":"Population-based SEER trend analysis of overall and cancer-specific survival in 5138 patients with gastrointestinal stromal tumor","volume":"15","author":"Guller \n              U,","year":"2015","unstructured":"Guller \n              U, \n            \n            \n              Tarantino \n              I, \n            \n            \n              Cerny \n              T, \n            \n            \n              Schmied \n              BM, \n            \n            \n              Warschkow \n              R. \n            \n          \n          Population-based SEER trend analysis of overall and cancer-specific survival in 5138 patients with gastrointestinal stromal tumor. BMC Cancer. 2015;15(1):557."},{"issue":"4","key":"i1543-2165-140-5-449-b17","series-title":"Gastrointest Endosc","first-page":"977","article-title":"Human epidermal growth factor receptor 2 testing in gastric and gastroesophageal junction adenocarcinomas: role of the gastroenterologist","volume":"81","author":"Park \n              JY,","year":"2015","unstructured":"Park \n              JY, \n            \n            \n              Dunbar \n              KB, \n            \n            \n              Vemulapalli \n              R, \n            \n            \n              Wang \n              DH, \n            \n            \n              Zhang \n              PJ. \n            \n          \n          Human epidermal growth factor receptor 2 testing in gastric and gastroesophageal junction adenocarcinomas: role of the gastroenterologist. Gastrointest Endosc. 2015;81(4):977\u2013982."},{"issue":"9911","key":"i1543-2165-140-5-449-b18","series-title":"Lancet","first-page":"31","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs \n              CS,","year":"2014","unstructured":"Fuchs \n              CS, \n            \n            \n              Tomasek \n              J, \n            \n            \n              Yong \n              CJ, \n            \n            et al. \n          Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31\u201339."},{"issue":"11","key":"i1543-2165-140-5-449-b19","series-title":"Lancet Oncol","first-page":"1224","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke \n              H,","year":"2014","unstructured":"Wilke \n              H, \n            \n            \n              Muro \n              K, \n            \n            \n              Van Cutsem \n              E, \n            \n            et al. \n          Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224\u20131235."},{"issue":"15","key":"i1543-2165-140-5-449-b20","series-title":"J Clin Oncol","first-page":"1960","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore \n              MJ,","year":"2007","unstructured":"Moore \n              MJ, \n            \n            \n              Goldstein \n              D, \n            \n            \n              Hamm \n              J, \n            \n            et al. \n          Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960\u20131966."},{"issue":"4","key":"i1543-2165-140-5-449-b21","series-title":"N Engl J Med","first-page":"378","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet \n              JM,","year":"2008","unstructured":"Llovet \n              JM, \n            \n            \n              Ricci \n              S, \n            \n            \n              Mazzaferro \n              V, \n            \n            et al. \n          Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u2013390."},{"issue":"5","key":"i1543-2165-140-5-449-b22","series-title":"Dig Dis Sci","first-page":"1122","article-title":"Sorafenib for treatment of hepatocellular carcinoma: a systematic review","volume":"57","author":"Xie \n              B,","year":"2012","unstructured":"Xie \n              B, \n            \n            \n              Wang \n              DH, \n            \n            \n              Spechler \n              SJ. \n            \n          \n          Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci. 2012;57(5):1122\u20131129."},{"issue":"7","key":"i1543-2165-140-5-449-b23","series-title":"Lancet Oncol","first-page":"627","article-title":"Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2\/3 randomised trial","volume":"14","author":"Crosby \n              T,","year":"2013","unstructured":"Crosby \n              T, \n            \n            \n              Hurt \n              CN, \n            \n            \n              Falk \n              S, \n            \n            et al. \n          Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2\/3 randomised trial. Lancet Oncol. 2013;14(7):627\u2013637."},{"issue":"3 suppl","key":"i1543-2165-140-5-449-b24","series-title":"J Clin Oncol","article-title":"The initial report of RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery","volume":"32","author":"Suntharalingam \n              M,","year":"2014","unstructured":"Suntharalingam \n              M, \n            \n            \n              Winter \n              K, \n            \n            \n              Ilson \n              DH, \n            \n            et al. \n          The initial report of RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery. J Clin Oncol. 2014;32(3 suppl):LBA6."},{"issue":"6","key":"i1543-2165-140-5-449-b25","series-title":"Lancet Oncol","first-page":"481","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial","volume":"14","author":"Waddell \n              T,","year":"2013","unstructured":"Waddell \n              T, \n            \n            \n              Chau \n              I, \n            \n            \n              Cunningham \n              D, \n            \n            et al. \n          Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):481\u2013489."},{"issue":"6","key":"i1543-2165-140-5-449-b26","series-title":"Am Fam Physician","first-page":"1759","article-title":"Update on colorectal cancer","volume":"61","author":"Rudy \n              DR,","year":"2000","unstructured":"Rudy \n              DR, \n            \n            \n              Zdon \n              MJ. \n            \n          \n          Update on colorectal cancer. Am Fam Physician. 2000;61(6):1759\u20131770, 1773\u20131774."},{"issue":"13","key":"i1543-2165-140-5-449-b27","series-title":"N Engl J Med","first-page":"905","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: irinotecan study group","volume":"343","author":"Saltz \n              LB,","year":"2000","unstructured":"Saltz \n              LB, \n            \n            \n              Cox \n              JV, \n            \n            \n              Blanke \n              C, \n            \n            et al. \n          Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: irinotecan study group. N Engl J Med. 2000;343(13):905\u2013914."},{"issue":"9209","key":"i1543-2165-140-5-449-b28","series-title":"Lancet","first-page":"1041","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard \n              JY,","year":"2000","unstructured":"Douillard \n              JY, \n            \n            \n              Cunningham \n              D, \n            \n            \n              Roth \n              AD, \n            \n            et al. \n          Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041\u20131047."},{"issue":"14S","key":"i1543-2165-140-5-449-b29","series-title":"J Clin Oncol","first-page":"3621","article-title":"N9741: FOLFOX (oxaliplatin (Oxal)\/5-fluorouracil (5-FU)\/leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU\/LV) in advanced colorectal cancer (CRC): final efficacy data from an intergroup study","volume":"22","author":"Goldberg \n              RM,","year":"2004","unstructured":"Goldberg \n              RM, \n            \n            \n              Sargent \n              DJ, \n            \n            \n              Morton \n              RF, \n            \n            et al. \n          N9741: FOLFOX (oxaliplatin (Oxal)\/5-fluorouracil (5-FU)\/leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU\/LV) in advanced colorectal cancer (CRC): final efficacy data from an intergroup study. J Clin Oncol. 2004;22(14S):3621."},{"issue":"16","key":"i1543-2165-140-5-449-b30","series-title":"J Clin Oncol","first-page":"2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont \n              A,","year":"2000","unstructured":"de Gramont \n              A, \n            \n            \n              Figer \n              A, \n            \n            \n              Seymour \n              M, \n            \n            et al. \n          Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938\u20132947."},{"issue":"1","key":"i1543-2165-140-5-449-b31","series-title":"J Clin Oncol","first-page":"136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti \n              S,","year":"2000","unstructured":"Giacchetti \n              S, \n            \n            \n              Perpoint \n              B, \n            \n            \n              Zidani \n              R, \n            \n            et al. \n          Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18(1):136\u2013147."},{"issue":"23","key":"i1543-2165-140-5-449-b32","series-title":"N Engl J Med","first-page":"2343","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andre \n              T,","year":"2004","unstructured":"Andre \n              T, \n            \n            \n              Boni \n              C, \n            \n            \n              Mounedji-Boudiaf \n              L, \n            \n            et al. \n          Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343\u20132351."},{"issue":"2","key":"i1543-2165-140-5-449-b33","series-title":"J Clin Oncol","first-page":"229","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand \n              C,","year":"2004","unstructured":"Tournigand \n              C, \n            \n            \n              Andre \n              T, \n            \n            \n              Achille \n              E, \n            \n            et al. \n          FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229\u2013237."},{"issue":"12","key":"i1543-2165-140-5-449-b34","series-title":"J Clin Oncol","first-page":"2006","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy \n              J,","year":"2008","unstructured":"Cassidy \n              J, \n            \n            \n              Clarke \n              S, \n            \n            \n              Diaz-Rubio \n              E, \n            \n            et al. \n          Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26(12):2006\u20132012."},{"issue":"4","key":"i1543-2165-140-5-449-b35","series-title":"Am J Clin Oncol","first-page":"350","article-title":"Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results","volume":"30","author":"Patt \n              YZ,","year":"2007","unstructured":"Patt \n              YZ, \n            \n            \n              Lee \n              FC, \n            \n            \n              Liebmann \n              JE, \n            \n            et al. \n          Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol. 2007;30(4):350\u2013357."},{"issue":"23","key":"i1543-2165-140-5-449-b36","series-title":"N Engl J Med","first-page":"2335","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz \n              H,","year":"2004","unstructured":"Hurwitz \n              H, \n            \n            \n              Fehrenbacher \n              L, \n            \n            \n              Novotny \n              W, \n            \n            et al. \n          Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335\u20132342."},{"issue":"12","key":"i1543-2165-140-5-449-b37","series-title":"J Clin Oncol","first-page":"2013","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz \n              LB,","year":"2008","unstructured":"Saltz \n              LB, \n            \n            \n              Clarke \n              S, \n            \n            \n              Diaz-Rubio \n              E, \n            \n            et al. \n          Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013\u20132019."},{"issue":"suppl 3","key":"i1543-2165-140-5-449-b38","series-title":"J Clin Oncol","first-page":"512","article-title":"RAISE: a randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp) [abstract]","volume":"33","author":"Tabernero \n              J,","year":"2015","unstructured":"Tabernero \n              J, \n            \n            \n              Cohn \n              A, \n            \n            \n              Obermannova \n              R, \n            \n            \n              Bodoky \n              G, \n            \n            \n              Garcia-Carbonero \n              R, \n            \n            \n              Ciuleanu \n              T. \n            \n          \n          RAISE: a randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp) [abstract]. J Clin Oncol. 2015;33(suppl 3):512."},{"issue":"15","key":"i1543-2165-140-5-449-b39","series-title":"J Clin Oncol","first-page":"2011","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem \n              E,","year":"2011","unstructured":"Van Cutsem \n              E, \n            \n            \n              Kohne \n              CH, \n            \n            \n              Lang \n              I, \n            \n            et al. \n          Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011\u20132019."},{"issue":"31","key":"i1543-2165-140-5-449-b40","series-title":"J Clin Oncol","first-page":"4706","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters \n              M,","year":"2010","unstructured":"Peeters \n              M, \n            \n            \n              Price \n              TJ, \n            \n            \n              Cervantes \n              A, \n            \n            et al. \n          Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4706\u20134713."},{"issue":"13","key":"i1543-2165-140-5-449-b41","series-title":"J Clin Oncol","first-page":"1658","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem \n              E,","year":"2007","unstructured":"Van Cutsem \n              E, \n            \n            \n              Peeters \n              M, \n            \n            \n              Siena \n              S, \n            \n            et al. \n          Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658\u20131664."},{"issue":"5","key":"i1543-2165-140-5-449-b42","series-title":"J Clin Oncol","first-page":"672","article-title":"A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer","volume":"27","author":"Hecht \n              JR,","year":"2009","unstructured":"Hecht \n              JR, \n            \n            \n              Mitchell \n              E, \n            \n            \n              Chidiac \n              T, \n            \n            et al. \n          A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27(5):672\u2013680."},{"issue":"6","key":"i1543-2165-140-5-449-b43","series-title":"N Engl J Med","first-page":"563","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol \n              J,","year":"2009","unstructured":"Tol \n              J, \n            \n            \n              Koopman \n              M, \n            \n            \n              Cats \n              A, \n            \n            et al. \n          Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360(6):563\u2013572."},{"issue":"9863","key":"i1543-2165-140-5-449-b44","series-title":"Lancet","first-page":"303","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey \n              A,","year":"2013","unstructured":"Grothey \n              A, \n            \n            \n              Van Cutsem \n              E, \n            \n            \n              Sobrero \n              A, \n            \n            et al. \n          Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303\u2013312."},{"issue":"13","key":"i1543-2165-140-5-449-b45","series-title":"JAMA","first-page":"1383","article-title":"Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial","volume":"307","author":"Alberts \n              SR,","year":"2012","unstructured":"Alberts \n              SR, \n            \n            \n              Sargent \n              DJ, \n            \n            \n              Nair \n              S, \n            \n            et al. \n          Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307(13):1383\u20131393."},{"issue":"13","key":"i1543-2165-140-5-449-b46","series-title":"JAMA","first-page":"1431","article-title":"Antitumor activity in metastatic disease does not predict efficacy in the adjuvant setting","volume":"307","author":"Segal \n              NH,","year":"2012","unstructured":"Segal \n              NH, \n            \n            \n              Saltz \n              LB. \n            \n          \n          Antitumor activity in metastatic disease does not predict efficacy in the adjuvant setting. JAMA. 2012;307(13):1431\u20131432."},{"issue":"23","key":"i1543-2165-140-5-449-b47","series-title":"J Clin Oncol","first-page":"3456","article-title":"Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803","volume":"25","author":"Saltz \n              LB,","year":"2007","unstructured":"Saltz \n              LB, \n            \n            \n              Niedzwiecki \n              D, \n            \n            \n              Hollis \n              D, \n            \n            et al. \n          Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25(23):3456\u20133461."},{"issue":"1","key":"i1543-2165-140-5-449-b48","series-title":"J Clin Oncol","first-page":"11","article-title":"Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08","volume":"29","author":"Allegra \n              CJ,","year":"2011","unstructured":"Allegra \n              CJ, \n            \n            \n              Yothers \n              G, \n            \n            \n              O'Connell \n              MJ, \n            \n            et al. \n          Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29(1):11\u201316."},{"issue":"15s","key":"i1543-2165-140-5-449-b49","series-title":"J Clin Oncol","first-page":"3534","article-title":"PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors [abstract]","volume":"28","author":"Kopetz \n              S,","year":"2010","unstructured":"Kopetz \n              S, \n            \n            \n              Desai \n              J, \n            \n            \n              Chan \n              E, \n            \n            et al. \n          PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors [abstract]. J Clin Oncol. 2010;28(15s):3534."},{"issue":"2","key":"i1543-2165-140-5-449-b50","series-title":"J Natl Cancer Inst","first-page":"84","article-title":"Ready or not: personal tumor profiling tests take off","volume":"103","author":"Garber \n              K.","year":"2011","unstructured":"Garber \n              K. \n            \n          \n          Ready or not: personal tumor profiling tests take off. J Natl Cancer Inst. 2011;103(2):84\u201386."},{"issue":"3","key":"i1543-2165-140-5-449-b51","series-title":"Crit Rev Oncol Hematol","first-page":"243","article-title":"Cancer of unknown primary (CUP)","volume":"54","author":"Pavlidis \n              N,","year":"2005","unstructured":"Pavlidis \n              N, \n            \n            \n              Fizazi \n              K. \n            \n          \n          Cancer of unknown primary (CUP). Crit Rev Oncol Hematol. 2005;54(3):243\u2013250."},{"issue":"1","key":"i1543-2165-140-5-449-b52","series-title":"JAMA Oncol","first-page":"40","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies","volume":"1","author":"Ross \n              JS,","year":"2015","unstructured":"Ross \n              JS, \n            \n            \n              Wang \n              K, \n            \n            \n              Gay \n              L, \n            \n            et al. \n          Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol. 2015;1(1):40\u201349."},{"issue":"4","key":"i1543-2165-140-5-449-b53","series-title":"JAMA Oncol","first-page":"466","article-title":"Whole-exome sequencing of metastatic cancer and biomarkers of treatment response","volume":"1","author":"Beltran \n              H,","year":"2015","unstructured":"Beltran \n              H, \n            \n            \n              Eng \n              K, \n            \n            \n              Mosquera \n              JM, \n            \n            et al. \n          Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol. 2015;1(4):466\u2013474."},{"issue":"12","key":"i1543-2165-140-5-449-b54","series-title":"Drug Discov Today","first-page":"1433","volume":"20","author":"Johnson \n              A,","unstructured":"Johnson \n              A, \n            \n            \n              Zeng \n              J, \n            \n            \n              Bailey \n              AM, \n            \n            et al. \n          The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discov Today. 20(12):1433\u20131438."},{"issue":"suppl 2","key":"i1543-2165-140-5-449-b55","series-title":"Cancer Inform","first-page":"45","article-title":"GeneMed: an informatics hub for the coordination of next-generation sequencing studies that support precision oncology clinical trials","volume":"14","author":"Zhao \n              Y,","year":"2015","unstructured":"Zhao \n              Y, \n            \n            \n              Polley \n              EC, \n            \n            \n              Li \n              MC, \n            \n            et al. \n          GeneMed: an informatics hub for the coordination of next-generation sequencing studies that support precision oncology clinical trials. Cancer Inform. 2015;14(suppl 2):45\u201355."},{"issue":"10","key":"i1543-2165-140-5-449-b56","series-title":"Nat Biotechnol","first-page":"908","article-title":"Performance comparison of exome DNA sequencing technologies","volume":"29","author":"Clark \n              MJ,","year":"2011","unstructured":"Clark \n              MJ, \n            \n            \n              Chen \n              R, \n            \n            \n              Lam \n              HY, \n            \n            et al. \n          Performance comparison of exome DNA sequencing technologies. Nat Biotechnol. 2011;29(10):908\u2013914."},{"issue":"1","key":"i1543-2165-140-5-449-b57","series-title":"Clin Chem","first-page":"213","article-title":"Clinical exome performance for reporting secondary genetic findings","volume":"61","author":"Park \n              JY,","year":"2015","unstructured":"Park \n              JY, \n            \n            \n              Clark \n              P, \n            \n            \n              Londin \n              E, \n            \n            \n              Sponziello \n              M, \n            \n            \n              Kricka \n              LJ, \n            \n            \n              Fortina \n              P. \n            \n          \n          Clinical exome performance for reporting secondary genetic findings. Clin Chem. 2015;61(1):213\u2013220."},{"issue":"1","key":"i1543-2165-140-5-449-b58","series-title":"Genome Med","first-page":"71","article-title":"Achieving high-sensitivity for clinical applications using augmented exome sequencing","volume":"7","author":"Patwardhan \n              A,","year":"2015","unstructured":"Patwardhan \n              A, \n            \n            \n              Harris \n              J, \n            \n            \n              Leng \n              N, \n            \n            et al. \n          Achieving high-sensitivity for clinical applications using augmented exome sequencing. Genome Med. 2015;7(1):71."},{"key":"i1543-2165-140-5-449-b59","series-title":"BMC Bioinformatics","first-page":"195","article-title":"Quantifying single nucleotide variant detection sensitivity in exome sequencing","volume":"14","author":"Meynert \n              AM,","year":"2013","unstructured":"Meynert \n              AM, \n            \n            \n              Bicknell \n              LS, \n            \n            \n              Hurles \n              ME, \n            \n            \n              Jackson \n              AP, \n            \n            \n              Taylor \n              MS. \n            \n          \n          Quantifying single nucleotide variant detection sensitivity in exome sequencing. BMC Bioinformatics. 2013;14:195."},{"issue":"1","key":"i1543-2165-140-5-449-b60","series-title":"Genome Med","first-page":"80","article-title":"Next-generation sequencing to guide cancer therapy","volume":"7","author":"Gagan \n              J,","year":"2015","unstructured":"Gagan \n              J, \n            \n            \n              Van Allen \n              EM. \n            \n          \n          Next-generation sequencing to guide cancer therapy. Genome Med. 2015;7(1):80."},{"issue":"4","key":"i1543-2165-140-5-449-b61","series-title":"Arch Pathol Lab Med","first-page":"481","article-title":"College of American Pathologists' laboratory standards for next-generation sequencing clinical tests","volume":"139","author":"Aziz \n              N,","year":"2015","unstructured":"Aziz \n              N, \n            \n            \n              Zhao \n              Q, \n            \n            \n              Bry \n              L, \n            \n            et al. \n          College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med. 2015;139(4):481\u2013493."},{"issue":"4","key":"i1543-2165-140-5-449-b62","series-title":"Cancers (Basel)","first-page":"2296","article-title":"Next-generation sequencing in clinical oncology: next steps towards clinical validation","volume":"6","author":"Bennett \n              NC,","year":"2014","unstructured":"Bennett \n              NC, \n            \n            \n              Farah \n              CS. \n            \n          \n          Next-generation sequencing in clinical oncology: next steps towards clinical validation. Cancers (Basel). 2014;6(4):2296\u20132312."},{"issue":"5","key":"i1543-2165-140-5-449-b63","series-title":"Cancer Treat Rev","first-page":"385","article-title":"The landscape of precision cancer medicine clinical trials in the United States","volume":"41","author":"Roper \n              N,","year":"2015","unstructured":"Roper \n              N, \n            \n            \n              Stensland \n              KD, \n            \n            \n              Hendricks \n              R, \n            \n            \n              Galsky \n              MD. \n            \n          \n          The landscape of precision cancer medicine clinical trials in the United States. Cancer Treat Rev. 2015;41(5):385\u2013390."},{"key":"i1543-2165-140-5-449-b64","series-title":"Annu Rev Pharmacol Toxicol","first-page":"9","article-title":"The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication","volume":"54","author":"Rask-Andersen \n              M,","year":"2014","unstructured":"Rask-Andersen \n              M, \n            \n            \n              Masuram \n              S, \n            \n            \n              Schioth \n              HB. \n            \n          \n          The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu Rev Pharmacol Toxicol. 2014;54:9\u201326."},{"key":"i1543-2165-140-5-449-b65","series-title":"Clin Chim Acta","first-page":"284","article-title":"The future of laboratory medicine\u2014a 2014 perspective","volume":"438","author":"Kricka \n              LJ,","year":"2015","unstructured":"Kricka \n              LJ, \n            \n            \n              Polsky \n              TG, \n            \n            \n              Park \n              JY, \n            \n            \n              Fortina \n              P. \n            \n          \n          The future of laboratory medicine\u2014a 2014 perspective. Clin Chim Acta. 2015;438:284\u2013303."},{"issue":"5","key":"i1543-2165-140-5-449-b66","series-title":"Mol Oncol","first-page":"967","article-title":"Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity","volume":"9","author":"Catenacci \n              DV.","year":"2015","unstructured":"Catenacci \n              DV. \n            \n          \n          Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol. 2015;9(5):967\u2013996."},{"issue":"133","key":"i1543-2165-140-5-449-b67","series-title":"Eur Respir Rev","first-page":"367","article-title":"New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response","volume":"23","author":"Menis \n              J,","year":"2014","unstructured":"Menis \n              J, \n            \n            \n              Hasan \n              B, \n            \n            \n              Besse \n              B. \n            \n          \n          New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. Eur Respir Rev. 2014;23(133):367\u2013378."},{"key":"i1543-2165-140-5-449-b68","series-title":"Am Soc Clin Oncol Educ Book","first-page":"71","article-title":"National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network","author":"Abrams \n              J,","year":"2014","unstructured":"Abrams \n              J, \n            \n            \n              Conley \n              B, \n            \n            \n              Mooney \n              M, \n            \n            et al. \n          National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book. 2014:71\u201376."},{"issue":"7","key":"i1543-2165-140-5-449-b69","series-title":"Cancer Discov","first-page":"685","article-title":"NCI prepares to launch MATCH trial","volume":"5","year":"2015","unstructured":"NCI prepares to launch MATCH trial. Cancer Discov. 2015;5(7):685."},{"issue":"3","key":"i1543-2165-140-5-449-b70","series-title":"Semin Oncol","first-page":"297","article-title":"Molecular analysis for therapy choice: NCI MATCH","volume":"41","author":"Conley \n              BA,","year":"2014","unstructured":"Conley \n              BA, \n            \n            \n              Doroshow \n              JH. \n            \n          \n          Molecular analysis for therapy choice: NCI MATCH. Semin Oncol. 2014;41(3):297\u2013299."},{"issue":"7","key":"i1543-2165-140-5-449-b71","series-title":"J Natl Cancer Inst","article-title":"NCI-MATCH launch highlights new trial design in precision-medicine era","volume":"107","author":"McNeil \n              C.","year":"2015","unstructured":"McNeil \n              C. \n            \n          \n          NCI-MATCH launch highlights new trial design in precision-medicine era. J Natl Cancer Inst. 2015;107(7):djv193."},{"issue":"9","key":"i1543-2165-140-5-449-b72","series-title":"J Clin Oncol","first-page":"1000","article-title":"Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial","volume":"33","author":"Lopez-Chavez \n              A,","year":"2015","unstructured":"Lopez-Chavez \n              A, \n            \n            \n              Thomas \n              A, \n            \n            \n              Rajan \n              A, \n            \n            et al. \n          Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol. 2015;33(9):1000\u20131007."},{"issue":"9","key":"i1543-2165-140-5-449-b73","series-title":"J Clin Oncol","first-page":"975","article-title":"Basket trials and the evolution of clinical trial design in an era of genomic medicine","volume":"33","author":"Redig \n              AJ,","year":"2015","unstructured":"Redig \n              AJ, \n            \n            \n              Janne \n              PA. \n            \n          \n          Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol. 2015;33(9):975\u2013977."},{"issue":"9","key":"i1543-2165-140-5-449-b74","series-title":"Clin Cancer Res","first-page":"2029","article-title":"Precision medicine for advanced pancreas cancer: the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial","volume":"21","author":"Chantrill \n              LA,","year":"2015","unstructured":"Chantrill \n              LA, \n            \n            \n              Nagrial \n              AM, \n            \n            \n              Watson \n              C, \n            \n            et al. \n          Precision medicine for advanced pancreas cancer: the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial. Clin Cancer Res. 2015;21(9):2029\u20132037."},{"issue":"8","key":"i1543-2165-140-5-449-b75","series-title":"Nat Rev Cancer","first-page":"457","article-title":"Evolving synergistic combinations of targeted immunotherapies to combat cancer","volume":"15","author":"Melero \n              I,","year":"2015","unstructured":"Melero \n              I, \n            \n            \n              Berman \n              DM, \n            \n            \n              Aznar \n              MA, \n            \n            \n              Korman \n              AJ, \n            \n            \n              Gracia \n              JL, \n            \n            \n              Haanen \n              J. \n            \n          \n          Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457\u2013472."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/140\/5\/article-p449.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/140\/5\/449\/1445950\/arpa_2015-0317-ra.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/140\/5\/article-p449.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/140\/5\/article-p449.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:06:45Z","timestamp":1770772005000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/140\/5\/article-p449.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":150,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2015-0317-ra","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}